Thermo Fisher Scientific CHEK2 Monoclonal Antibody (PCRP-CHEK2-1A4)

Applications

Tested Dilution

Publications

Western Blot (WB)

1-2 µg/mL

-

Immunocytochemistry (ICC/IF)

1-2 µg/mL

-

Flow Cytometry (Flow)

1-2 µg/10^6 cells

-

Immunoprecipitation (IP)

1-2 µg/100-500 µg lysate

-

Peptide Array (Array)

Assay-dependent

-

Immunoelectrophoresis (IE)

Assay-dependent

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Mouse / IgG2b

Class

Monoclonal

Type

Antibody

Clone

PCRP-CHEK2-1A4

Immunogen

Recombinant fragment of human CHEK2 corresponding to protein domain

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

200 µg/mL

Purification

Protein A/G

Storage buffer

PBS with 0.05% BSA

Contains

0.05% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

Product Specific Information

Antibody is stable for 24 months.

Positive Control: HeLa or HCT 116cells.Human testis, spleen or colon. Cellular Localization: Nucleus.

Specificity Comments: Recognizes a serine/threonine protein kinase that is a required check-point to mediate cell cycle arrest, activation of DNA repair and apoptosis.In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. Also, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors.

Predicted to react with Mouse and Rat

Target Information

CHEK2 (CHK2) is a serine/threonine kinase and a component of the DNA damage checkpoint pathway. A mutation in CHK2 has been linked to cancer. CHK2 is activated by DNA damage and phosphorylates several modulators of cell cycle control including tumor suppressor proteins. In addition, Chk2 can phosphorylate BRCA1, allowing BRCA1 to restore survival after DNA damage. Chk2 is a putative tumor suppressor protein, with mutations in to the Chk2 gene linked to Li-Fraumeni syndrome, a familiar cancer usually associated with inherited mutations in TP53. Also, mutations in CHK2 are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.